To include your compound in the COVID-19 Resource Center, submit it here.

With Foresite backing $90M round, GenapSys rolls out a smaller, cheaper sequencer

An opportunity for decentralized sequencing attracted Foresite to lead GenapSys' $90M series C

GenapSys has netted a $90 million series C led by Foresite Capital to introduce a genetic sequencer that is designed to deliver high-accuracy results at low cost without the need for a central laboratory.

GenapSys Inc.'s shoebox-sized sequencer costs $10,000 and uses sensors on chips to measure the electrical signature of a

Read the full 510 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers